and more big pharma shenanigans

so, what's wrong with this picture??? (see New York Times article: http://www.nytimes.com/2014/12/08/business/paid-to-promote-eye-drug-and-prescribing-it-widely-.html?ref=business&_r=0 ).

--Genentech came out with Lucentis, a new product in 2006 used by ophthalmologists to treat macular degeneration
--It costs $2000/dose
--it is "nearly equivalent" to Avastin and was approved only for this same indication. Several studies have concluded that "Lucentis has no significant advantage over its cheaper alternative"
--Avastin costs $50/dose
--Lucentis is one of Medicare's most expensive drugs, costing the federal government $1 billion in 2010 . Avastin was still much more commonly used, though Medicare spent only $27 million on it that year. In fact a study in 2011 showed that if all patients on Lucentis had received Avastin, the government would have saved $1.4 billion

--and, many of the doctors "who were top billers for Lucentis were among the highest paid consultants for Genentech, earning thousands of dollars to help promote the drug"
--1/2 of the 20 doctors who received the most money from Genentech were among the highest users, "billing for higher amounts of Lucentis than 75% of their peers", and also earning $8500 to $37000 in 5 months in 2013 for consultant and speaking fees.
--Genentech has even been paying "rebates" to doctors who use lots of Lucentis.